Why the study?
What are the real-world patterns of initiation, titration, and persistence for guideline-directed medical therapies in heart failure?
What are the real-world patterns of initiation, titration, and persistence for guideline-directed medical therapies in heart failure?
Real-world evidence highlights significant clinical inertia in heart failure management, with delayed initiation and poor uptitration of novel therapies, though dapagliflozin shows better persistence.
Emphasizes need to overcome GDMT inertia in HF practice; extends evidence on real-world implementation gaps.
Initiation of novel GDMTs is delayed compared with other GDMTs. Few patients received target doses of GDMTs requiring uptitration. Persistence was higher for dapagliflozin than other GDMTs.
No takes yet. Share an insight, caveat, or question.
Savarese et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: